Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152

Neuroendocrinology

Volumn 90, Issue 1, 2009, Pages 15-18

  Emons, Günter ^a,d   Sindermann, Herbert ^b   Engel, Jürgen ^b   Schally, Andrew V ^c   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Æterna Zentaris GmbH   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Department of Gynecology and Obstetrics ^*  (Germany)

Author keywords

AN 152; Gonadotropin releasing hormone; Luteinizing hormone releasing hormone; Receptor targeted therapy

Indexed keywords

2 PYRROLINODOXORUBICIN; ANTHRACYCLINE DERIVATIVE; CA 125 ANTIGEN; CARBOPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; PACLITAXEL;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURGERY; CLINICAL TRIAL; DISSEMINATED CANCER; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; HUMAN; IN VIVO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTASIS; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SHORT SURVEY; SPLEEN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UTERINE TUBE CARCINOMA; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG DESIGN; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, LHRH;

EID: 67651113824     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000225410     Document Type: Short Survey

References (15)

1. Emons G, Ortmann O, Schulz KD, Schally AV: Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997; 8: 355-362. (Pubitemid 28034420)
2. Ho MN, Delgado CH, Owens GA, Steller MA: Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin- releasing hormone agonist on ovarian cancer cell growth. Fertil Steril 1997; 67: 870-876.
3. Emons G, Müller V, Ortmann O, Schulz KD: Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998; 65: 199-206. (Pubitemid 28335607)
4. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Evidence for tight coupling of gonadotropin- releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 1998; 83: 427-431. (Pubitemid 28496517)
5. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropinreleasing hormone receptor in endometrial cancer cells. Int J Oncol 1998; 13: 97-100. (Pubitemid 28267501)
6. Yin H, Cheng KW, Hwa HL, Peng C, Auersperg N, Leung PC: Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sci 1998; 62: 2015-2023. (Pubitemid 28239714)
7. Seppala M, Wahlstrom T: Identification of luteinizing hormone-releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer 1980; 26: 267-268. (Pubitemid 10049394)
8. Gründker C, Günthert AR, Westphalen S, Emons G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146: 1-14. (Pubitemid 34126412)
9. Fekete M, Wittliff JL, Schally AV: Characteristics and distribution of receptors for [DTRP 6 ]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137-147. (Pubitemid 20199263)
10. Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G: Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002; 187: 528-537.
11. Schally AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20: 1247-1262. (Pubitemid 29512447)
12. Schally AV, Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999; 141: 1-14.
13. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Gründker C, Schally AV, Emons G: Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000; 17: 1063-1069.
14. Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G: Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 2004; 191: 1164-1172. (Pubitemid 39421567)
15. Günthert AR, Gründker C, Bongertz T, Nagy A, Schally AV, Emons G: Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance- 1 (MDR-1) system. Breast Cancer Res Treat 2004; 87: 255-264. (Pubitemid 39505942)